Sundhedsstyrelsens nye retningslinier - DSOG

tologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized
trial. J Natl Cancer Inst 2000;92:397-402.
4
Kjær SK, Svare EI, Munk C, Lidang M, Hølund B, Norrild B et al. Vejledende retningslinjer for
anvendelse af HPV-testning i Danmark. Klaringsrapport nr. 8, København 2002.
5
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N et al. European guidelines for quality
assurance in cervical cancer screening. 2. ed. European Commission, 2008.
6
Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up
management strategies for women with human papillomavirus-negative atypical squamous cells of
undetermined significance. Obstet Gynecol 2007;109:1325-31.
7
Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence,
type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination
program in Denmark. Int J Cancer 2008;123:1864-70.
8
Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F et al. Human papillomavirus triage
for young women with atypical squamous cells of undetermined significance. Obstet Gynecol
2006;107:822-9.
9
Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB et al. Predicting CIN2+ when detecting
HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of
women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-6.
10
Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G et al. Comparison of predictors
for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidem
Biomar 2008;17:3033-42.
11
Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence--implications
for cervical disease progression and monitoring. J Med Virol 2004;73:65-70.
12
Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the
APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin
Virol 2009;45:S55-S61.
13
Reuschenbach M, Clad A, von Knebel DC, Wentzensen N, Rahmsdorf J, Schaffrath F et al. Performance
of p16(INK4a)-cytology, HPV mRNA, and HPV-DNA testing to identify high grade
cervical dysplasia in women with abnormal screening results. Gynecol.Oncol. 2010.
14
Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. Human papillomavirus E6/E7 mRNA expression
in women younger than 30 years of age. Gynecol Oncol 2006;100:95-100.
15
Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and
2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
J Natl Cancer Inst 2005;97:1066-71.
Screening for livmoderhalskkræft. Anbefalinger 2011
80